|
|
||||||||
1 Department of Internal Medicine, University of Iowa, Iowa City, Iowa
Correspondence and requests for reprints should be addressed to D. Michael Shasby, M.D., Professor, Department of Internal Medicine, C33-I, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242. E-mail: michael-shasby{at}uiowa.edu
Activation of the type 2 protease–activated (PAR2) receptor interrupts E-cadherin adhesion and decreases the transepithelial resistance (TER) of epithelium (1). E-cadherin adhesive function depends on the association of E-cadherin with β-catenin, and this interaction is regulated by phosphorylation of tyrosines in β-catenin. We tested the hypothesis that loss of cadherin adhesion and compromise of epithelial barrier integrity upon activation of the PAR2 receptor is due to phosphorylation of tyrosines 489 and/or 654 in β-catenin. L-cells, stably expressing E-cadherin, and MDCK cells were transfected with FLAG-tagged wild-type (wt) or mutant β-catenin, converting tyrosine 142, 489, or 654 to phenylalanine (wt, Y142F, Y489F, or Y654F). PAR2 activation increased tyrosine phosphorylation of β-catenin. PAR2 activation interrupted adhesion to an immobilized E-cadherin–Fc fusion protein of L-E-cad and MDCK cells expressing wt or Y142F β-catenin, but did not interrupt adhesion of L-E-cad and MDCK cells expressing Y489F or Y654F β-catenins. PAR2 activation decreased the TER of monolayers of MDCK cells expressing wt or Y142F β-catenin by 40 to 45%. PAR2 activation did not decrease the TER of monolayers of MDCK cells expressing Y489F or Y654F β-catenin. We conclude that PAR2 interrupts E-cadherin adhesion by phosphorylating tyrosines 489 and/or 654 in β-catenin, and that PAR2 decreases the resistance of epithelium solely by interrupting E-cadherin adhesion. Intact E-cadherin adhesion is essential to lung epithelial and pulmonary microvascular barriers. β-catenin Y489 and Y654 are phosphorylated by Abl and Src kinases, respectively. Src-Abl inhibitors are clinically available and may provide a mechanism to limit the effects of inflammation on vital E-cadherin epithelial and endothelial barriers in the lung.
FOOTNOTES
Support: NHLBI HL33540 (D.M.S.).
Conflict of Interest Statement: M.C.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.S.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.M.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
(Received in original form July 17, 2007; accepted in final form October 16, 2007)
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |